

Post-trial access to drugs for rare diseases: an integrative review

Jefferson Westarb Mota¹, Fernando Hellmann¹, Jucélia Maria Guedert², Marta Verdi¹, Sílvia Cardoso Bittencourt³

1. Universidade Federal de Santa Catarina, Florianópolis/SC, Brasil. 2. Hospital Infantil Joana de Gusmão, Florianópolis/SC, Brasil. 3. Secretaria de Estado da Saúde de Santa Catarina, Florianópolis/SC, Brasil.

Abstract

This study is an integrative literature review to analyze the scientific production about post-trial drug access by participants of clinical trials for rare diseases. The search was carried out in the Virtual Health Library, Embase, PubMed, SciELO, Scopus and Web of Science databases, covering 21 studies. Two categories emerged from the analysis: clinical research with orphan drugs and market regulation; and access to orphan drugs: background, globalization and the right to health. The first analyzes issues related to the number of patients with rare diseases, the efficacy and safety of these studies and the cost and price of medications. The second addresses the historical background of post-trial access, the globalization of clinical trials and the difficulties to ensure the right to post-trial access to orphan drugs. Few articles addressed post-trial drug access by participants with rare diseases as a central issue, which points to the importance of further studies on this subject.

Keywords: Ethics, research. Rare diseases. Bioethics. Clinical trial.

Resumo

Acesso a medicamentos para doenças raras no pós-estudo: revisão integrativa

A fim de analisar a produção científica acerca do acesso a medicamentos no pós-estudo por participantes de ensaios clínicos com doenças raras, realizou-se revisão integrativa da literatura nas bases Biblioteca Virtual em Saúde, Embase, PubMed, SciELO, Scopus e Web of Science, abrangendo 21 estudos. No processo analítico, surgiram duas categorias: pesquisa clínica com drogas órfãs e regulação do mercado; e acesso a drogas órfãs: história, globalização e direito à saúde. A primeira analisa questões relativas à quantidade de pacientes com doenças raras, à eficácia e à segurança dessas pesquisas e aos custos e preços dos medicamentos. A segunda trata do panorama histórico do acesso pós-estudo, da globalização dos ensaios clínicos e das dificuldades para efetivar o direito ao acesso a drogas órfãs no pós-estudo. Poucos artigos abordaram o acesso ao medicamento no pós-estudo por participantes com doenças raras como questão central, o que aponta a importância de mais estudos sobre esse tema.

Palavras-chave: Ética em pesquisa. Doenças raras. Bioética. Ensaio clínico.

Resumen

Acesso a medicamentos para enfermedades raras en el posestudo: una revisión integradora

Se pretende analizar la producción científica sobre el acceso a medicamentos para enfermedades raras en el posestudo a partir de una revisión integradora en las bases de datos Biblioteca Virtual en Salud, Embase, PubMed, SciELO, Scopus y Web of Science, que encontraron 21 estudios. Surgieron dos categorías en el análisis: investigación clínica con medicamentos huérfanos y regulación del mercado; y acceso a medicamentos huérfanos: historia, globalización y derecho a la salud. La primera examina el número de pacientes con enfermedades raras, la eficacia y seguridad de los estudios, así como los costes y precios de los medicamentos. La segunda aborda el panorama histórico del acceso posestudo, la globalización de los ensayos clínicos y las dificultades para materializar el derecho al acceso a medicamentos huérfanos en el posestudo. Pocos estudios plantean el acceso a estos medicamentos en el posestudo, y son necesarios más estudios sobre el tema.

Palabras clave: Ética en investigación. Enfermedades raras. Bioética. Ensayo clínico.

The authors declare no conflict of interest.

Rare diseases affect a significant percentage of the population, which reveals an important health issue regarding the availability of treatment and the ethical aspects related to research and the need for public policies for these individuals¹⁻³. Also known as orphan diseases, such pathologies mainly affect children. Diseases that affect 65 people per 100,000⁴⁻⁶ are classified as rare. When they affect one patient in every 50,000 people, they are defined as very rare, ultra-rare or super-rare⁷.

There is no consensus on the number of rare and ultra-rare diseases⁸. However, it is estimated at around 8 thousand, accounting for a quarter of all known diseases worldwide. Most of these pathologies have a genetic origin, unlike others such as cancer and infectious, toxic and chronic diseases. Global infant mortality among people with rare diseases reaches 30%. This percentage is greater in peripheral countries such as Brazil, where diagnosis and access to experimental clinical research and to potential therapies from this process are deficient⁸.

By its nature, an experimental clinical trial is not the same as a treatment and, in the case of rare diseases, the search for therapies and the belief in a cure can lead to therapeutic mistakes. In this sense, normative standards for research ethics in clinical trials of this type must be transparent and based on documents that regulate and guide research governance⁹.

The process of searching for so-called orphan drugs consists of clinical trials aimed at developing safe therapies for such pathologies¹⁰. The development of these drugs is beneficial to the area of unmet needs; however, the pharmaceutical industry has little interest in developing and marketing them¹¹. In addition, this process must be based on internationally established ethical foundations so that the design and practice of research are fair, especially in relation to drug supply^{12,13}.

The guarantee of access to beneficial interventions by participants of a clinical trial after its completion is called *post-trial access*¹⁴. This principle appears internationally from the year 2000, in the *Declaration of Helsinki* (DH) of the World Medical Association (WMA)¹⁵,

a guiding framework for Brazilian ethical standards, which aim to ensure the rights of research participants in relation to scientific objectives, during or after the clinical trial¹⁶. However, the latest version of DH, dated 2013, has not been applied to research in Brazil and the country's current official documents do not mention it for disagreeing with its positions regarding the use of placebos and post-trial access.

In this context, the Brazilian National Research Ethics Committee/Research Ethics Committees (CEP/Conep) system is responsible for evaluating human research ethics in Brazil and has advanced the defense of the rights of Brazilian research participants, especially for being part of the social control framework of the Unified Health System (SUS)¹⁷.

The standard that broadly covers the issue of post-trial access is Resolution 466/2012 of the National Health Council (CNS), which approves guidelines and regulatory standards for research with humans. In Item III.3, this resolution provides that research with humans should:

d) ensure that when the study is over, the sponsor grants all participants free and indefinite access to the best prophylactic, diagnostic and therapeutic methods that have proven to be effective;
*d.1) access will also be guaranteed in the interval between the end of individual participation and the end of the study, in which case said guarantee may be given through an extension study, according to a duly justified analysis of the participant's attending physician*¹⁸.

Conep's resolutions on research ethics also apply to rare diseases, and the resolutions of the Collegiate Board (RDC) of the National Health Surveillance Agency (Anvisa) regulate the availability of drugs for people with rare diseases that have not yet been approved to be marketed in Brazil. For example, RDC 38/2013¹⁹ addresses expanded access, compassionate drug use and post-trial access in general, and is not specific to rare diseases. This resolution was amended in October 2019 by RDC 311/2019²⁰, which refers the issue of the provision of post-trial drugs to Conep resolutions.

CNS Resolution 563/2017²¹, in turn, specifically addresses post-trial access to drugs for ultra-rare diseases, that is, it does not apply to rare diseases. With this resolution, mandatory post-trial access, previously unrestricted, indefinite and the exclusive responsibility of the industry, is now restricted to five years, counted from the definition of the price in reais by the Drug Market Regulation Chamber (CMED).

Currently, Bill 200/2015²², which has been approved by the Federal Senate and is being debated as Bill 7082/2017²³ in the Chamber of Deputies, calls into question the protection of research participants in Brazil by proposing new resolutions for Brazilian research from an ethical-normative point of view, posing a threat to the right to post-trial access²⁴.

The production of drugs for rare diseases must be seen as a government issue to avoid the imposition of a capitalist and market-oriented view. Faced with the specificities of rare and ultra-rare diseases, added to the forces that tend to minimize the role of the state and maximize the health market, the market for limited use drugs presents ethical conflicts that evidence the collapse of public interests in relation to private ones.

This article analyzes the scientific production on access to post-trial drugs by participants in clinical trials for rare diseases.

Method

The integrative review²⁵⁻³² consisted of six steps:

1. Identification of the problem;
2. Sample selection;
3. Categorization of selected studies;
4. Critical analysis of the studies included in the review;
5. Description of results;
6. Interpretation and discussion of results in order to gather and synthesize existing knowledge on the subject³¹.

The guiding question of the study was: "What ethical issues are found in the literature on access to pharmacotherapy by participants in clinical trials for rare diseases?" To answer it, a bibliographic search was carried out in the following databases: Virtual Health Library (VHL), Embase, PubMed, SciELO, Scopus and Web of Science. The search was adapted to the specificities of each database, leading to the development of thematic blocks associated with Boolean operators:

- Thematic block 1: "*doenças raras*," "rare diseases," "orphan diseases."
- Thematic block 2: "*ética*," "ethics," "*bioética*," "bioethics," "*pesquisa ética*," "ethical research."
- Thematic block 3: "*acesso ao pós-estudo*," "post-trial access," "access to post-clinical trial," "post-trial responsibilities," "post-trial obligation," "access to pharmaceuticals," "access to medicines and health technologies," "access to essential drugs and health technologies."


A reverse exploratory search was carried out based on studies found during the initial search process.

The inclusion criteria were studies published as scientific papers (original or review), in any language, between 2000 and 2020. Theses, dissertations, essays, reviews, books or abstracts of proceedings of scientific events were excluded, in addition to works published outside the established time frame.

Clarivate Analytics' EndNote X8 software was used as an auxiliary tool to build databases and select papers. Subsequently, the chosen studies were analyzed and identified, as shown in the flowchart (Figure 1) of the data collection process according to the PRISMA method³³. The search for papers was carried out between September and October 2020.

In the initial step, the data were systematized into two categories determined a posteriori. In the final step, the data were discussed by grouping criteria, compiling information and important trends to address the theme.

Figure 1. Flowchart of the study selection steps of the integrative review (2021)



Results

The search in the databases resulted initially in 464 studies, of which 241 remained after the exclusion of duplicates. Following the screening

of keywords, title and abstract, 179 did not fit the theme, leading to a total of 62, which were read in full, resulting in 19 studies, to which were added two works in the reverse search. The final sample consisted of 21 studies, according to the proposed selection criteria (chart 1).

Chart 1. Selected studies according to authors, year, country of origin, language, journal and database

Authors	no.	Year	Country/origin	Language	Journal/origin	Database
Annemans, Makady; 2020 ¹²	1	2020	Belgium	English	<i>Orphanet Journal of Rare Diseases</i>	Scopus
Blin and collaborators; 2020 ³⁴	2	2020	France	English	<i>Therapies</i>	Embase, PubMed, Scopus, Web of Science
Bouwman, Sousa, Pina; 2020 ¹¹	3	2020	Portugal	English	<i>Health Policy and Technology</i>	Embase, Scopus, Web of Science
Dal-Ré and collaborators; 2020 ³⁵	4	2020	Spain	Spanish	<i>Anales de Pediatría</i>	PubMed, Scopus
Naud; 2019 ¹⁶	5	2019	Brazil	Portuguese	<i>Revista Brasileira de Bioética</i>	Reverse search

continues...



Chart 1. Continuation

Authors	no.	Year	Country/origin	Language	Journal/origin	Database
Gelinas and collaborators; 2019 ³⁶	6	2019	USA	English	<i>Contemporary Clinical Trials</i>	Scopus
Saviano and collaborators; 2019 ³⁷	7	2019	Italy	English	<i>Sustainability</i>	Web of Science
Chaves Restrepo and collaborators; 2018 ³⁸	8	2018	Colombia	English	<i>Value in Health</i>	Embase
Pace and collaborators; 2018 ³⁹	9	2018	Australia	English	<i>Health Policy</i>	Scopus, Web of Science
van Egmond-Fröhlich, Schmitt; 2018 ⁴⁰	10	2018	Austria	German	<i>Monatsschrift Kinderheilkunde</i>	Embase, Scopus, Web of Science
Hasford, Koch; 2017 ¹	11	2017	Germany	German	<i>Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz</i>	VHL, PubMed, Scopus, Web of Science
Rodriguez-Monguio, Spargo, Seoane-Vazquez; 2017 ⁴¹	12	2017	USA	English	<i>Orphanet Journal of Rare Diseases</i>	VHL, PubMed, Scopus, Web of Science
Mastroleo; 2016 ⁴²	13	2016	Argentina	English	<i>Developing World Bioethics</i>	VHL, Scopus
Dallari; 2015 ⁴³	14	2015	Brazil	Portuguese	<i>Revista Bioética</i>	SciELO
Silva, Sousa; 2015 ⁷	15	2015	Brazil	Portuguese	<i>Caderno de Saúde Pública</i>	VHL, SciELO
Rhee; 2015 ⁴⁴	16	2015	USA	English	<i>Ama Journal of Ethics</i>	VHL, Scopus
Rosselli, Rueda, Solano; 2012 ⁴⁵	17	2012	Colombia	English	<i>Journal of Medical Ethics</i>	Web of Science
Dainesi, Goldbaum; 2011 ⁴⁶	18	2011	Brazil	Portuguese	<i>Revista da Associação Médica Brasileira</i>	Reverse search
Barrera, Galindo; 2010 ⁴⁷	19	2010	Colombia	English	<i>Advances in Experimental Medicine and Biology</i>	VHL, PubMed, Scopus, Web of Science
Boy, Schramm; 2009 ⁴⁸	20	2009	Brazil	Portuguese	<i>Caderno de Saúde Pública</i>	VHL
Grady; 2005 ⁴⁹	21	2005	USA	English	<i>Yale Journal of Health Policy, Law, and Ethics</i>	VHL, PubMed, Scopus, Web of Science

VHL: Virtual Health Library; USA: United States of America

Bibliometric data indicate the number of studies published each year: four studies (19.1%) in 2020; three studies (14.3%) per year in 2019, 2018 and 2015; two studies (9.4%) in 2017; one study (4.8%) in 2016; one study per year in 2012, 2011, 2010, 2009 and 2005, totaling five studies (23.8%).

Regarding the origin of the studies and respective authors, Brazil has five (23.8%); United States, four (19.0%); Colombia, three (14.3%); and Germany, Austria, Argentina, Australia, Belgium, Spain, France, Italy and Portugal,

one study each, totaling nine (42.9%). Regarding the language of publication, 13 studies (61.9%) are in English, five are in Portuguese (23%), two are in German (9.5%) and one is in Spanish (4.8%).

Based on content analysis, the studies were grouped into two categories:

- a. Clinical research with orphan drugs and financial market regulation;
- b. Access to orphan drugs: background, globalization and the right to health, comprising different themes (Chart 2).

Chart 2. Categories, emerging themes and descriptions identified in the articles on rare diseases (2021)

Clinical research with orphan drugs and market regulation	
Emerging theme	Description
Population of patients with rare diseases	Small size of patient population; characteristics of manifestation and geopolitical distribution of rare diseases converge on the problem of patient enrollment in clinical trials (Annemans, Makady; 2020 ¹² ; Barrera, Galindo; 2010 ⁴⁷ ; Dallari; 2015 ⁴³ ; Hasford, Koch; 2017 ¹ ; Rhee; 2015 ⁴⁴ ; Rodriguez-Monguio, Spargo, Seoane-Vazquez; 2017 ⁴¹ ; Rosselli, Rueda, Solano; 2012 ⁴⁵).
Efficacy and safety	Compliance with efficacy and safety requirements in clinical research of drugs for rare diseases (Annemans, Makady; 2020 ¹² ; Barrera, Galindo; 2010 ⁴⁷ ; Chaves and collaborators; 2018 ³⁸ ; Hasford, Koch; 2017 ¹ ; Pace and collaborators; 2018 ³⁹).
Cost and price	The high cost of the development and post-marketing of drugs for rare diseases poses obstacles to access by the target population, revealing the industry's efforts to recover development costs, use of funding and judicialization to ensure access (Barrera, Galindo; 2010 ⁴⁷ ; Blin and collaborators; 2020 ³⁴ ; Boy, Schramm; 2009 ⁴⁸ ; Dal-Ré and collaborators; 2020 ³⁵ ; Rosselli, Rueda, Solano; 2012 ⁴⁵ ; Saviano and collaborators; 2019 ³⁷ ; van Egmond-Fröhlich, Schmitt; 2018 ⁴⁰).
Market regulation	The regulatory process for orphan drugs is carried out by regulatory bodies in each country, sometimes influenced by patient organizations, but market monopoly and price elasticity reveal regulatory flaws that reduce access and favor profit. (Bouwman, Sousa, Pina; 2020 ¹¹ ; Dallari; 2015 ⁴³ ; Rhee; 2015 ⁴⁴ ; Saviano and collaborators; 2019 ³⁷ ; van Egmond-Fröhlich, Schmitt; 2018 ⁴⁰).
Access to orphan drugs: background, globalization and the right to health	
Emerging themes	Description
Historical background	International and national documents/standards disseminate post-trial provision of beneficial orphan drugs (Dainesi, Goldbaum; 2011 ⁴⁶ ; Dallari; 2015 ⁴³ ; Gelinas and collaborators; 2019 ³⁶ ; Grady; 2005 ⁴⁹ ; Mastroleo; 2016 ⁴² ; Naud; 2019 ¹⁶ ; Silva, Sousa; 2015 ⁷).
Globalization of clinical trials	Contemporary evolution of clinical trials through post-trial access to orphan drugs (Boy, Schramm; 2009 ⁴⁸ ; Dainesi, Goldbaum; 2011 ⁴⁶ ; Grady; 2005 ⁴⁹ ; Mastroleo; 2016 ⁴² ; Rosselli, Rueda, Solano; 2012 ⁴⁵ ; Silva, Sousa; 2015 ⁷).
Right to health	Post-trial provision of orphan drugs as a right to health (Dallari; 2015 ⁴³ ; Rodriguez-Monguio, Spargo, Seoane-Vazquez; 2017 ⁴¹).

Discussion

Clinical research with orphan drugs

The themes related to the development of orphan drugs in clinical trials were addressed by 17 papers. The authors comprehensively report how the prevalence of rare diseases, which is lower than those of other diseases, becomes representative when they are grouped. The low prevalence justifies the difficulty of recruiting participants, spread around the world, and reveals problems in quantifying the size of the population and ensuring fair and equitable participation in research^{1,12,41,43-45,47}.

Annemans and Makady¹² argue that the incidence and prevalence of rare diseases can be

seen as a set of uncertainties, since the exact size of the affected population, the characteristics of the subpopulations and the clinical manifestations of the diseases are variable. Rodriguez-Monguio, Spargo and Seoane-Vasquez⁴¹ show that as there is no consensus on the size of the population of patients with rare diseases, practical intervention on this dimension is necessary.

The authors also cross population growth with the growth of the identification of new rare diseases⁴¹. The prevalence of the disease as a promoter of the clinical development of orphan drugs is problematized, since it conflicts with the concept of justice, as populations usually tend to grow, which, in percentage terms, would reduce and exclude people with rare diseases over time⁴¹.



The scant and dispersed distribution of rare diseases in the population makes it difficult to recruit for clinical trials (particularly in phases I, II and III) the number of participants required for the approval of any drug, including orphan drugs. The authors also define this population as vulnerable and unprotected when it comes to access in peripheral countries^{47,48}.

Accessible participation in clinical trials of drugs for patients with rare diseases requires relevant policies and reflection, mainly from the population point of view, to provide justice and equity⁴⁹. In this sense, Silva, Ventura and Castro⁵⁰ discuss equal opportunities in the use of healthcare services and access to clinical trials for orphan drugs. This shows that the distribution of such opportunities is hindered by obstacles related to geographic location and eligibility criteria for study participants, with exclusions of population groups in clinical trials and consequent loss of benefit.

In Brazil, Bill 231/2012⁵¹ provided the creation of the National Research Fund for Rare and Neglected Diseases (FNPDRN), reserving 30% of funds from the Health Research Promotion Program, an important initiative to fight inequalities in research fostered by the development of drugs, vaccines and therapies for rare diseases. However, the bill was vetoed in its entirety by President Jair Bolsonaro in 2019 for allegedly compromising the feasibility of said program and reducing private interest in the matter⁵².

When the principle of justice is absent in clinical trials for rare diseases, the consequence is poor access to health care, as equitable distribution is affected by several issues, such as disease prevalence, population size and characteristics, and research inclusion criteria^{1,12,41,43-45,47}.

Seeking distributive justice in the case of rare diseases means questioning the rules and format with which this distribution is done according to the characteristics of the population. For Boy and Schramm⁴⁸, access to clinical research and drugs to treat rare diseases in peripheral countries, places with blatant social asymmetries and inequalities, affects the vulnerable population harshly. Those authors advocate the need for legitimate public policies based on the principle of equity, guaranteeing formal equality.

In general, the articles analyzed argue that the ethical standards that guide the requirements of efficacy and safety in the development of clinical research and production of drugs for rare diseases must be respected^{1,34,39,47}. Ethical standards of information, consent and conduct of studies must be followed regardless of disease frequency¹.

Barrera and Galindo⁴⁷ add that research on drugs for rare diseases must also strictly comply with the requirements of efficacy and safety, ideally at the lowest possible cost, as these drugs will be used in highly vulnerable and unprotected people. Treatment effect and durability must also be provided, based on confidence interval, group heterogeneity, dosage and adverse events¹².

However, Blin and collaborators state that *some clinical trials that may not be ethical for frequent diseases may be acceptable for rare diseases* [statement regarding lack of power due to small number of available patients and heterogeneity, short trials that do not address the most relevant clinical outcome and early use of biomarkers before their qualification...]. *Otherwise, there is a risk that new drugs will never be developed for complicated rare diseases and that efforts will be concentrated on relatively frequent diseases with a well-known and controllable development pipeline*⁵³.

This shows the need to criticize the defense of easing of post-trial access, as it is essential to strengthen the perspective of the right to access as a right to health. This view is adopted by Pace and collaborators³⁹ when they address the ethical framework for the creation, governance and evaluation of accelerated access programs, presenting an overview of the case of rare diseases. Accelerating the process of obtaining orphan drugs, the authors argue, may have built-in risks, whether physical (resulting from adverse drug effects) or psychological³⁹.

In turn, Hasford and Koch¹ stress that methodological limits in clinical research exist regardless of whether it relates to rare or frequent diseases and must be respected, showing the importance of planning the study in the best way possible so as to minimize harm.

Hasford and Koch¹ argue that an important aspect in ethical evaluation in clinical trials for rare diseases is the biometric quality of the study's design, size, sample and statistical analysis,

as weak methodologies proposed in clinical trials with humans are considered unethical. Therefore, there is a need to ensure methodological criteria based on ethical standards that certify the efficacy and safety of clinical trials in the development of these drugs.

Several studies focus on such efficacy and safety. Most argue that the research method should be guided by ethical rigor. However, some authors suggest that, on the other hand, ethical rigor may limit clinical research, due to the very heterogeneity of diseases³⁴. Such rigor must ensure compliance with the requirements of efficacy and safety in planned trials for common diseases and, especially, the safety of participants and respect for human rights. Malleability and acceleration in the rare disease research process put participants at risk.

For Blin and collaborators³⁴, clinical trials are intervention studies that aim to analyze and evaluate one or more drugs in order to intervene in the progression of a rare disease or a group of them, implying high economic costs. The guarantee of access to participation in clinical studies and the benefits arising from them may be jeopardized by commercial clinical research, and it is up to research ethics and public health policies to problematize this issue^{34,35,37,40,43,45,47,48}.

The high prices of orphan drugs may reflect the need to recover development costs with a small group of patients³⁴. However, Saviano and collaborators³⁷ question whether those prices fairly reflect the costs incurred in development or are aimed at generating profit. The fact is that all clinical research is costly, which, in the case of rare diseases, gives rise to an unregulated market⁴⁰.

In addition to the possible benefits, some authors reflect on how patients have access to multicenter clinical trials and orphan drugs^{35,48} (the debate on the responsibility for guaranteeing the provision of the post-study drug will be addressed in the second section of this paper). Thus, mechanisms such as funding and judicialization are mentioned. The development of clinical trials for rare diseases may be thwarted by lack of funding, although there are alternatives.

Dal-Ré and collaborators³⁵ describe how patients occasionally finance clinical trials through crowdfunding. This mechanism has been used in

the United States for about 40 years and raises ethical questions, mainly because it prioritizes the research needs of wealthy people rather than society as a whole. Self-financing is also advocated as long as ethical research requirements are met³⁵.

Boy and Schramm⁴⁸ address the search for access to orphan drugs in developing countries and use the example of Brazil, where many drugs already approved in the European Union, United States, Australia and Asian countries are not on the Ministry of Health's list of exceptional drugs, with provision depending on judicialization. The literature also stresses that access via judicialization to drugs in experimental or non-approved phases may pose risks to patients⁵⁴.

Although it can ensure fair access to drugs by patients, judicialization implies costly and ethically questionable public spending, especially in countries with scarce public resources for health. The regulatory process for the production, development and control of orphan drugs is usually done by competent bodies, such as the Food and Drugs Administration (FDA) in the United States, the European Medicines Agency (EMA) in Europe and Anvisa in Brazil. Despite the extensive regulatory process required by these bodies, Rhee⁴⁴ states that many orphan drugs are currently available but not always accessible due to their high cost.

The author points out that the lack of market regulation raises concerns about pharmaceutical companies creating a monopoly that prevents buyers from negotiating prices⁴⁴. The combination of monopoly and price elasticity results from faulty market regulation, with drug producers setting profitable prices under pressure from investors.

The search for profit is evident in the behavior of drug producers, showing that the economic risk assumed, given the relatively small market for orphan drugs, can be offset by financial incentives (flexibilization, tax credits and patents), which is observed especially in developed countries, as stated by Dallari⁴³.

Patient organizations, such as the European Organization for Rare Diseases (Eurordis) in Europe and the National Organization for Rare Disorders (Nord) in the United States, play important roles in the field of rare diseases, mainly by encouraging the development of research and

providing funding¹¹. In addition, they work to raise public awareness, collecting information, providing support and information to those affected, keeping patient records and networking with universities, industry and health authorities. The analyzed authors also emphasize that patient organizations can influence standards and the problematization of market monopoly¹¹.

Access to orphan drugs

The theme related to the provision of post-trial orphan drugs was addressed in nine articles. The authors reported that ethical aspects related to research with humans are historically governed by several documents.

Each author provides a documentary historical background of corrections and incorporations of guiding ethical principles, identifying DH, the *Belmont Report*, the *International Ethical Guidelines for Biomedical Research Involving Humans Subjects*, of the World Health Organization (WHO), the *Universal Declaration on Bioethics and Human Rights* (UDBDH) and the *International Declaration on Human Genetic Data*^{7,16,36,42,43,46,49} as the main documents in guiding ethical research with humans. DH and UDBDH are highlighted as regulations that address access to post-trial drugs.

HD is recognized worldwide as a benchmark for ethical research⁴⁶. Silva and Sousa⁷ explain that access to post-trial technologies by research participants has been problematized since 2000. The authors reveal that DH incorporated the principle of post-trial access in clinical research in the 2000s—in its fifth revision—and that such endorsement produced differing interpretations. Therefore, WMA issued a clarification in 2004, triggering the debate on post-trial access in interventions that proved to be beneficial^{7,16,36,42,43,46,49}.

The latest version of DH⁵⁵, revised in 2013, concisely addresses this principle, explaining in Article 34 the need for provisions, agreed between sponsors, researchers and governments of the host countries of the clinical research, for post-trial access to all participants who still need intervention identified as beneficial in the study. DH recommends that relevant

information during the informed consent process and the study outcomes be disclosed to the participants in the consent form⁴³.

Mastroleo⁴² argues that the 2013 revision of DH abandons the ambiguous language found in previous versions and identifies the responsible agents. However, the author criticizes the removal of references to access to appropriate care other than drug-related and to obligatory access to post-trial information⁴².

In Brazil, the evolution of regulations on post-trial access began with CNS Resolution 196/1996¹⁷, complemented by CNS Resolution 251/1997⁵⁶, which specifically addresses research for new drugs, vaccines and diagnostic tests.

The Brazilian ethical regulation that addresses the principle of post-trial access currently in force is Resolution CNS 466/2012¹⁸, which regulates ethics in clinical research, protects research participants and defines post-trial access as a sponsor's duty^{17,18,56}. The National Policy for Comprehensive Care for People with Rare Diseases was only implemented in 2014 by Ordinance 199/2014⁴, expanding previous restrictive conduct with a predominant focus on medicine.

Grady⁴⁹ and Dainesi and Goldbaum⁴⁶ consider the issue of the principle of post-trial access a challenge, revealing that it has been a subject of discussion since the late 1980s, when it was associated with the continuity of treatment of participants in HIV/AIDS studies. Other articles also address the development of antiretrovirals⁵⁷⁻⁶³. International and national regulations reveal an extensive debate on the incorporation of the principle of post-trial access.

Naud¹⁶ addresses the complexity of this debate, revealing that regulations are not capable of covering all types of diseases. The author also points to the fact that all research must have its own evaluation, based on the singularities of each disease, population and their needs¹⁶. The position defended by Naud¹⁶ is considered to relate to the "easing" of ethical research standards based on those singularities.

Dainesi and Goldbaum⁴⁶ view the dissemination of the principle of post-trial access as a contemporary concern, especially in the context of other illnesses. It is noted that the organization of HIV patients played a role in inducing this principle, which gained

momentum when it was inserted in HD in 2000. In the case of the provision of orphan drugs to participants with rare diseases, usually chronic and progressive, the challenges relate to a specific context that hinders access to medicines.

Different authors address the effect of globalization on the expansion of clinical research^{42,46,49}. For Dainesi and Goldbaum⁴⁶, globalization raises new questions in the scientific community and the principle of post-trial access emerges as a demand in this period. Similarly, Mastroleo⁴² states that providing the transition of research participants to appropriate health care when the study ends is a global problem. Thus, continuity of medical care, including treatment, is based on an ethical responsibility to compensate volunteering participants who subjected themselves to clinical research biases⁴⁶.

Before the 1980s, development of drugs for rare diseases was insufficient and focused on palliative measures that aimed to circumvent the seriousness of those diseases⁷. At that time, initial concerns emerged about methodological, regulatory and ethical aspects in the development and production of orphan drugs. Reflecting on the healthcare aspect of post-trial access in that period was remarkably hypothetical.

The scientific development that enabled the creation of enzyme and gene therapies, which are the basis of most drugs for rare diseases, was boosted after the 1980s. Boy and Schramm⁴⁸ point to a contemporary evolution of clinical trials based on biotechnical, scientific progress, which can be seen in current pharmaceutical research of drugs for rare diseases.

The authors also state that the global insertion of orphan drugs occurred progressively, with developed countries as pioneers, and explain that drugs are currently being developed for patients with rare diseases, but with a focus on economic aspects. The rarity of the disease and the prevalence in peripheral countries slow down development for purely profitable reasons⁴⁸.

Dainesi and Goldbaum⁴⁶ reveal that clinical trials of rare diseases and treatment with orphan drugs after the conclusion of a research require attention particularly in developing countries, where participants are more vulnerable. This ethical issue relates to social conditions that interfere with

the autonomy of the investigated subjects, putting their interests at risk.

Rosselli, Rueda and Solano⁴⁵ analyze the situation of social vulnerability in developing countries in research on mucopolysaccharidosis VI. This rare disease affects indigenous ethnic groups in Colombia, where access to developed drugs is compromised by geographic marginalization and frequent institutional distrust.

Dallari⁴³ mentions that the need to provide ethical protection in developing countries must go beyond research participants to benefit the community. Dainesi and Goldbaum⁴⁶ state that adequately designed and conducted clinical research, with methodologies that comply with maximum ethical rigor, must be extended to the entire community.

Mastroleo⁴² stresses that access to post-trial orphan drugs is not just a problem for countries with few or average resources. The author highlights cases of uninsured or underinsured research participants in the United States and of former participants of clinical trials in the United Kingdom whose therapy was not provided by the United Kingdom National Health Service (NHS)⁴².

In a 2003 editorial, the scientific journal *The Lancet*⁶⁴ states that participants from wealthy nations are usually able to obtain the best available treatment at the end of a clinical trial, while in the developing world researchers leave the respective countries where the research was conducted and the participants may be left with nothing. It adds that the obligation to provide post-trial access is closely linked to the vulnerability of the participants.

In analyzing the distributive justice of post-trial drugs in Brazil, Deucher⁶⁵ observed, based on a qualitative and exploratory study, that patients with serious and life-threatening diseases do not suffer negligence in access to post-trial drugs. The author also highlighted that foreign pharmaceutical companies without national representation have difficulty understanding the need to provide post-trial drugs.

Therefore, it is perhaps appropriate to reflect that pharmaceutical multinationals and conglomerates choose to ignore the problems of countries with few resources, especially in terms of social vulnerability. Dallari⁴³ argues that the world community must remain committed

to providing access to necessary health care and treatment, especially post-trial access.

The globalization of clinical trials for rare diseases is currently growing and sheds light on ethical issues that guide post-trial access to orphan drugs, both in peripheral and rich countries. It is noted that the outsourcing of clinical trials to peripheral countries is marked by economic issues that often hinder the right of access to post-trial drugs by research participants who need them. In this context, the right to health supports the fundamental guarantee of post-trial access to orphan drugs^{41,43}.

Dallari⁴³ analyzes the ethical conflict involved in post-trial access and in rare diseases, showing that essential products, such as orphan drugs, cannot be viewed solely from the point of view of health, as they are associated with predominant social, economic and technological factors.

The constitutional law of Western countries often includes the right to life as one of its basic moral principles. Based on that and on DUBDH, Rodriguez-Monguio, Spargo and Seoane-Vasquez⁴¹ proposed that the above-stated principle can be understood as a right to health when related to the use of orphan drugs in the treatment of potentially fatal diseases. That makes it possible to analyze the right of access to orphan drugs as part of the right to health.

Thus, the state fulfills its constitutional duty to protect the right to health when it regulates clinical research, creating duties between sponsors and researchers and thereby protecting participants entering in an asymmetrical relationship of information and power that subjects them to high risk. It is in this perspective that the obligation to ensure post-trial access must be understood, a condition that must be guaranteed by the state within the scope of its duty to protect, and not as a means of exempting itself from the duty to provide. Access to post-trial orphan drugs is considered a right of access to medicine, regardless of how that access is made possible.

Final considerations

During the process of reading and composing the categories resulting from the bibliographic survey, issues emerged that address not only post-trial access

to drugs by participants affected by rare diseases, but also questions about clinical research with orphan drugs. Although this theme, configured in the first category, does not directly address the main theme of the research, it is nevertheless relevant to a comprehensive understanding of post-trial access to orphan drugs.

The reduced size of the population of patients with rare diseases is a factor that narrows down the discussion of post-trial drug access, given that the production of orphan drugs is basically market-oriented rather than guided by the health needs of that population. The geopolitical distribution of these diseases also encourages discussion about the issue of enrolling in clinical trials and increases global asymmetries. The high costs of the production of orphan drugs and their reduced and unregulated market are obstacles to guaranteeing post-trial access and favorable to industry profits.

Although this is a relatively recent issue, different regulations address in different ways specific questions about the principle of post-trial access by participants in research with rare diseases, and there is no international consensus on the provision of orphan drugs to patients who need them. Furthermore, it was observed that the globalization of clinical trials is due to commercial interests, especially to lower the costs of drug development. This economic factor is another barrier to post-trial access to orphan drugs.

Lastly, the authors address the right to health and the right to life as principles that guide and defend the right to post-trial access. In Brazil, post-trial access to researched products is ensured by ethical regulations in unequivocal and non-negotiable terms. In times of budget cuts in the health area, the only sure way to guarantee this right to Brazilian citizens with rare diseases who are volunteers in clinical research is to ensure that the sponsor continues providing them with the medication that benefits them for as long as needed.

Discussions on research ethics from the perspective of social justice contribute to ensure the right to post-trial drug access, insofar as they highlight the need for public policy in this regard. It is therefore essential to reflect and take a stand against threats that may place that right in jeopardy.

References

1. Hasford J, Koch A. Ethische Aspekte der klinischen Prüfung bei seltenen Erkrankungen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz [Internet]. 2017 [acesso 2 dez 2021];60(5):556-62. DOI: 10.1007/s00103-017-2537-6
2. Mariz S, Reese JH, Westermarck K, Greene L, Goto T, Hoshino T et al. Worldwide collaboration for orphan drug designation. Nat Rev Drug Discov [Internet]. 2016 [acesso 2 dez 2021];15(6):440-1. DOI: 10.1038/nrd.2016.80
3. Parra JG. Medicamentos huérfanos: regulación y controversias. Boletín de Información Farmacoterapéutica de Navarra [Internet]. 2015 [acesso 25 fev 2021];23(1):1-13. Disponível: <https://bit.ly/3R3AWGw>
4. Brasil. Ministério da Saúde. Portaria nº 199, de 30 de janeiro de 2014. Institui a Política Nacional de Atenção Integral às Pessoas com Doenças Raras, aprova as Diretrizes para Atenção Integral às Pessoas com Doenças Raras no âmbito do Sistema Único de Saúde (SUS) e institui incentivos financeiros de custeio. Diário Oficial da União [Internet]. Brasília, 2014 [acesso 2 dez 2021]. Disponível: <https://bit.ly/3TemIUW>
5. Federhen A, Vairo FP, Vanzella C, Boer AP, Baldo G, Giugliani R. Pesquisa clínica e doenças raras: a situação no Brasil. J Bras Econ Saúde [Internet]. 2014 [acesso 2 dez 2021];supl(1):17-23. Disponível: <https://bit.ly/3pGHuPD>
6. Kaplan W, Wirtz VJ, Mantel-Teeuwisse A, Stolk P, Duthey B, Laing R, editors. Priority medicines for Europe and the World – 2013 Update [Internet]. Geneva: WHO; 2013 [acesso 2 dez 2021]. Capítulo 6.19, Rare diseases; p. 148-150. Disponível: <https://bit.ly/3cUqtOV>
7. Silva EN, Sousa TRV. Avaliação econômica no âmbito das doenças raras: isto é possível? Cad Saúde Pública [Internet]. 2015 [acesso 25 fev 2021];31(3):1-11. DOI: 10.1590/0102-311x00213813
8. Luz GS, Silva MRS, DeMontigny F. Doenças raras: itinerário diagnóstico e terapêutico das famílias de pessoas afetadas. Acta Paul Enferm [Internet]. 2015 [acesso 2 dez 2021];28(5):395-400. DOI: 10.1590/1982-0194201500067
9. Woods S, McCormack P. Disputing the ethics of research: the challenge from bioethics and patient activism to the interpretation of the Declaration of Helsinki in clinical trials. Bioethics [Internet]. 2013 [acesso 2 dez 2021];27(5):243-50. DOI: 10.1111/j.1467-8519.2011.01945.x
10. London AJ. How should we rare disease allocation decisions? Hastings Cent Rep [Internet]. 2012 [acesso 2 dez 2021];42(1):3. DOI: 10.1002/hast.3
11. Bouwman ML, Sousa JJS, Pina MET. Regulatory issues for orphan medicines: a review. Health Policy Technol [Internet]. 2020 [acesso 2 dez 2021];9(1):115-21. DOI: 10.1016/j.hlpt.2019.11.008
12. Annemans L, Makady A. TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases. Orphanet J Rare Dis [Internet]. 2020 [acesso 2 dez 2021];15(1):127. DOI: 10.1186/s13023-020-01370-3
13. Hernberg-Stahl E, Reljanovic M. Orphan drugs: understanding the rare disease market and its dynamics. Cambridge: Woodhead; 2013.
14. Dainesi SM, Goldbaum M. Pesquisa clínica como estratégia de desenvolvimento em saúde. Rev Assoc Med Bras [Internet]. 2012 [acesso 25 fev 2021];58(1):2-6. DOI: 10.1590/S0104-42302012000100002
15. Associação Médica Mundial. Declaração de Helsinque: princípios éticos para as pesquisas médicas em seres humanos [Internet]. 2000 [acesso 3 dez 2021]. Disponível: <https://bit.ly/3cobpce>
16. Naud LM. Doenças ultrarraras e o fornecimento do medicamento pós-estudo. Rev Bras Bioét [Internet]. 2019 [acesso 2 dez 2021];15(e12):1-16. DOI: 10.26512/rbb.v15.2019.22880
17. Conselho Nacional de Saúde. Resolução nº 196, de 10 de outubro de 1996. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Diário Oficial da União [Internet]. Brasília, nº 201, p. 21082-21085, 10 out 1996 [acesso 2 dez 2021]. Seção 1. Disponível: <https://bit.ly/3zyvPH7>

18. Conselho Nacional de Saúde. Resolução nº 466, de 12 de dezembro de 2012. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos e revoga as Resoluções CNS nos. 196/96, 303/2000 e 404/2008. Diário Oficial da União [Internet]. Brasília, p. 59, 13 jun 2013 [acesso 2 dez 2021]. Seção 1. Disponível: <https://bit.ly/3w4T2yR>
19. Agência Nacional de Vigilância Sanitária. Resolução RDC nº 38, de 12 de agosto de 2013. Aprova o regulamento para os programas de acesso expandido, uso compassivo e fornecimento de medicamento pós-estudo. Diário Oficial da União [Internet]. Brasília; 2013 [acesso 2 dez 2021]. Disponível: <https://bit.ly/3Cx86Kh>
20. Conselho Nacional de Saúde. Resolução nº 311, de 10 de outubro de 2019. Altera a Resolução da Diretoria Colegiada - RDC nº 38, de 12 de agosto de 2013, que aprova o regulamento para os programas de acesso expandido, uso compassivo e fornecimento de medicamento pós-estudo. Diário Oficial da União [Internet]. Brasília, n. 201, p. 105, 16 out 2019 [acesso 2 dez 2021]. Seção 1. Disponível: <https://bit.ly/3PODerW>
21. Conselho Nacional de Saúde. Resolução nº 563, de 10 de novembro de 2017. Define diretrizes e ações no âmbito das pesquisas envolvendo pessoas com doenças ultrarraras no Brasil. Diário Oficial da União [Internet]. Brasília, n. 236, p. 109, 11 dez 2017 [acesso 3 dez 2021]. Seção 1. Disponível: <https://bit.ly/3PMwOJH>
22. Brasil. Senado Federal. Projeto de Lei nº 200, de 7 de abril de 2015. Dispõe sobre princípios, diretrizes e regras para a condução de pesquisas clínicas em seres humanos por instituições públicas ou privadas [Internet]. Brasília: Senado Federal; 2015 [acesso 3 dez 2021]. Disponível: <https://bit.ly/3QPmCkV>
23. Brasil. Senado Federal. Projeto de Lei nº 7082, 13 de março de 2017. Dispõe sobre a pesquisa clínica com seres humanos e institui o Sistema Nacional de Ética em Pesquisa Clínica com Seres Humanos [Internet]. Brasília: Senado Federal; 2017 [acesso 3 dez 2021]. Disponível: <https://bit.ly/3CvqmdZ>
24. Vargas T. Entrevista: coordenadora fala do contexto atual do CEP/ENSP, das ameaças do PL 200 e dos 20 anos de atuação do Comitê da Escola. Portal Fiocruz Notícia [Internet]. 2017 [acesso 2 dez 2021]. Disponível: <https://bit.ly/3wxGgtA>
25. Botelho LLR, Cunha CCA, Macedo M. O método da revisão integrativa nos estudos organizacionais. Revista Eletrônica Gestão e Sociedade [Internet]. 2011 [acesso 2 dez 2021];5(11):121-36. DOI: 10.21171/ges.v5i11.1220
26. Broome ME. Integrative literature reviews for the development of concepts. In: Rodgers BL, Knafl KA, editors. Concept development in nursing: foundations, techniques, and applications [Internet]. 2ª ed. Philadelphia: W.B. Saunders; 2000 [acesso 2 dez 2021]. p. 231-50. Disponível: <https://bit.ly/3cqdAMw>
27. Cooper HM. Scientific guidelines for conducting integrative research reviews. Rev Educ Res [Internet]. 1982 [acesso 2 dez 2021];52(2):291-302. DOI: 10.3102/00346543052002291
28. Ferenhof HA, Fernandes RF. Desmistificando a revisão de literatura como base para redação científica: método SFF. Revista ACB [Internet]. 2016 [acesso 2 dez 2021];21(3):550-63. Disponível: <https://bit.ly/3e0JFus>
29. Ganong LH. Integrative reviews of nursing research. Res Nurs Health [Internet]. 1987 [acesso 2 dez 2021];10(1):1-11. DOI: 10.1002/nur.4770100103
30. Melnyk BM, Fineout-Overholt E. Making the case for evidence-based practice and cultivating a spirit of inquiry. In: Melnyk BM, Fineout-Overholt E, editors. Evidence-based practice in nursing and healthcare: a guide to best practice [Internet]. 2ª ed. Philadelphia: Lippincott Williams & Wilkins; 2011 [acesso 2 dez 2021]. p. 3-24. Disponível: <https://bit.ly/3CBHFDI>
31. Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs [Internet]. 2005 [acesso 2 dez 2021];52(5):546-53. DOI: 10.1111/j.1365-2648.2005.03621.x
32. Ercole FF, Melo LS, Alcoforado CLGC. Revisão integrativa versus revisão sistemática. Rev Min Enferm [Internet]. 2014 [acesso 2 dez 2021];18(1):9-11. DOI: 10.5935/1415-2762.20140001
33. Galvão TF, Pansani TSA, Harrad D. Principais itens para relatar revisões sistemáticas e meta-análises: a recomendação PRISMA. Epidemiol Serv Saúde [Internet]. 2015 [acesso 2 dez 2021];24(2):335-42. DOI: 10.5123/S1679-49742015000200017

34. Blin O, Lefebvre MN, Rascol O, Micallef J. Orphan drug clinical development. *Therapies* [Internet]. 2020 [acesso 2 dez 2021];75(2):141-7. DOI: 10.1016/j.therap.2020.02.004
35. Dal-Ré R, Palau F, Guillén-Navarro E, Ayuso C. Ensayos clínicos en enfermedades raras financiados por los participantes. *An Pediatr* [Internet]. 2020 [acesso 2 dez 2021];93(4):267.e1-9. DOI: 10.1016/j.anpedi.2020.03.019
36. Gelinas L, Crawford B, Kelman A, Bierer BE. Relocation of study participants for rare and ultra-rare disease trials: ethics and operations. *Contemp Clin Trials* [Internet]. 2019 [acesso 2 dez 2021];84:105812. DOI: 10.1016/j.cct.2019.105812
37. Saviano M, Barile S, Caputo F, Lettieri M, Zanda S. From rare to neglected diseases: a sustainable and inclusive healthcare perspective for reframing the orphan drugs issue. *Sustainability* [Internet]. 2019 [acesso 2 dez 2021];11:1289. DOI: 10.3390/su11051289
38. Chaves Restrepo ÁP, Cuestas JA, Yucuma D, Rosselli D. PSY185: alternative methodologies implemented by HTA agencies for orphan drugs: a scoping review. *Value Health* [Internet]. 2018 [acesso 2 dez 2021];21(supl 3):S468. DOI: 10.1016/j.jval.2018.09.2759
39. Pace J, Ghinea N, Kerridge I, Lipworth W. An ethical framework for the creation, governance and evaluation of accelerated access programs. *Health Policy* [Internet]. 2018 [acesso 2 dez 2021];122(9):984-90. DOI: 10.1016/j.healthpol.2018.07.014
40. van Egmond-Fröhlich A, Schmitt K. Öffentliche Lenkung und Preisbegrenzung für Orphan-drugs. *Monatsschrift Kinderheilkunde* [Internet]. 2018 [acesso 2 dez 2021];166(9):785-97. Disponível: <https://bit.ly/3pJMseb>
41. Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs? *Orphanet J Rare Dis* [Internet]. 2017 [acesso 2 dez 2021];12(1):1. DOI: 10.1186/s13023-016-0551-7
42. Mastroleo I. Post-trial obligations in the Declaration of Helsinki 2013: classification, reconstruction and interpretation. *Dev World Bioeth* [Internet]. 2016 [acesso 2 dez 2021];16(2):80-90. DOI: 10.1111/dewb.12099
43. Dallari SG. Fornecimento do medicamento pós-estudo em caso de doenças raras: conflito ético. *Rev. bioét. (Impr.)* [Internet]. 2015 [acesso 2 dez 2021];23(2):256-66. DOI: 10.1590/1983-80422015232064
44. Rhee TG. Policymaking for orphan drugs and its challenges. *AMA J Ethics* [Internet]. 2015 [acesso 2 dez 2021];17(8):776-9. DOI: 10.1001/journalofethics.2015.17.8.pfor2-1508
45. Rosselli D, Rueda JD, Solano M. Ethical and economic considerations of rare diseases in ethnic minorities: the case of mucopolysaccharidosis VI in Colombia. *J Med Ethics* [Internet]. 2012 [acesso 2 dez 2021];38(11):699-700. DOI: 10.1136/medethics-2011-100204
46. Dainesi SM, Goldbaum M. Fornecimento de medicamento investigacional após o fim da pesquisa clínica: revisão da literatura e das diretrizes nacionais e internacionais. *Rev Assoc Med Bras* [Internet]. 2011 [acesso 2 dez 2021];57(6):710-6. DOI: 10.1590/S0104-42302011000600021
47. Barrera LA, Galindo GC. Ethical aspects on rare diseases. In: Posada de la Paz M, Groft SC, editors. *Rare diseases epidemiology*. Berlin: Springer; 2010. p. 493-511.
48. Boy R, Schramm FR. Bioética da proteção e tratamento de doenças genéticas raras no Brasil: o caso das doenças de depósito lisossomal. *Cad Saúde Pública* [Internet]. 2009 [acesso 2 dez 2021];25(6):1276-84. DOI: 10.1590/S0102-311X2009000600010
49. Grady C. The challenge of assuring continued post-trial access to beneficial treatment. *Yale J Health Policy Law Ethics* [Internet]. 2005 [acesso 2 dez 2021];5(1): article 15. Disponível: <https://bit.ly/3pLiBSJ>
50. Silva CF, Ventura M, Castro CGSO. Bioethical perspective of justice in clinical trials. *Rev. bioét. (Impr.)* [Internet]. 2016 [acesso 2 dez 2021];24(2):292-303. DOI: 10.1590/1983-80422016242130

51. Brasil. Senado Federal. Projeto de Lei nº 231, de 5 de julho de 2012. Cria o Fundo Nacional de Pesquisa para Doenças Raras e Negligenciadas (FNPDRN) e dá outras providências [Internet]. Brasília: Senado Federal; 2012 [acesso 3 dez 2021]. Disponível: <https://bit.ly/3QT2a2z>
52. Brasil. Senado Federal. Governo veta projeto que garantia recursos para pesquisa de doenças raras. Agência Senado [Internet]. 2019 [acesso 2 dez 2021]. Disponível: <https://bit.ly/3PS6v50>
53. Blin O, Lefebvre MN, Rascol O, Micallef J. Op. cit. p. 144. Tradução livre.
54. Oliveira AG, Silveira D. Medicamentos órfãos: doenças raras e a judicialização da saúde. *Infarma* [Internet]. 2015 [acesso 2 dez 2021];27(4):203-4. DOI: 10.14450/2318-9312.v27.e4.a2015.pp203-204
55. World Medical Association. Declaração de Helsinque: princípios éticos para pesquisa médica envolvendo seres humanos [Internet]. 2013 [acesso 2 dez 2021]. Disponível: <https://bit.ly/3RdZWKS>
56. Conselho Nacional de Saúde. Resolução nº 251, de 7 de agosto de 1997. Aprova normas de pesquisa envolvendo seres humanos para a área temática de pesquisa com novos fármacos, medicamentos, vacinas e testes diagnósticos [Internet]. Brasília: Ministério da Saúde; 1997 [acesso 2 dez 2021]. Disponível: <https://bit.ly/3dRmump>
57. Cabral MML, Schindler HC, Abath FGC. Regulamentações, conflitos e ética da pesquisa médica em países em desenvolvimento. *Rev Saúde Pública* [Internet]. 2006 [acesso 2 dez 2021];40(3):521-7. DOI: 10.1590/S0034-89102006000300022
58. Cohen ERM, O'Neill JM, Joffres M, Upshur REG, Mills E. Reporting of informed consent, standard of care and post-trial obligations in global randomized intervention trials: a systematic survey of registered trials. *Dev World Bioeth* [Internet]. 2009 [acesso 2 dez 2021];9(2):74-80. DOI: 10.1111/j.1471-8847.2008.00233.x
59. Lunes R, Uribe MV, Torres JB, Garcia MM, Alvares-Teodoro J, Acurcio FA, Guerra AA Jr. Who should pay for the continuity of post-trial health care treatments? *Int J Equity Health* [Internet]. 2019 [acesso 2 dez 2021];18:26. DOI: 10.1186/s12939-019-0919-0
60. Millum J. Post-trial access to antiretrovirals: who owes what to whom? *Bioethics* [Internet]. 2011 [acesso 2 dez 2021];25(3):145-54. DOI: 10.1111/j.1467-8519.2009.01736.x
61. Paul A, Merritt MW, Sugarman J. Implementing post-trial access plans for HIV prevention research. *J Med Ethics* [Internet]. 2018 [acesso 2 dez 2021];44(5):354-8. DOI: 10.1136/medethics-2017-104637
62. Shaffer DN, Yebei VN, Ballidawa JB, Sidle JE, Greene JY, Meslin EM et al. Equitable treatment for HIV/AIDS clinical trial participants: a focus group study of patients, clinician researchers, and administrators in western Kenya. *J Med Ethics* [Internet]. 2006 [acesso 2 dez 2021];32(1):55-60. DOI: 10.1136/jme.2004.011106
63. Sofaer N, Strech D. Reasons why post-trial access to trial drugs should, or need not be ensured to research participants: a systematic review. *Public Health Ethics* [Internet]. 2011 [acesso 2 dez 2021];4(2):160-84. DOI: 10.1093/phe/phr013
64. One standard, not two. *Lancet* [Internet]. 2003 [acesso 2 dez 2021];362(9389):1005. DOI: 10.1016/S0140-6736(03)14444-3
65. Deucher KLAL. Análise da justiça distributiva no fornecimento de medicações após estudos clínicos no Brasil [dissertação]. São Paulo: Universidade de São Paulo; 2009.

Jefferson Westarb Mota – Master – jeffe12@hotmail.com

 0000-0002-1389-7967

Fernando Hellmann – PhD – fernando.hellmann@ufsc.br

 0000-0002-4692-0545

Jucélia Maria Guedert – PhD – juceliaguedert@ig.com.br

 0000-0002-7425-7568

Marta Verdi – PhD – marta.verdi@ufsc.br

 0000-0001-7090-9541

Silvia Cardoso Bittencourt – PhD – scbflor@hotmail.com

 0000-0002-7502-2613

Correspondence

Fernando Hellmann – Departamento de Saúde Pública. Campus Universitário Reitor João David Ferreira Lima, s/n, Trindade CEP 88040-900. Florianópolis/SC, Brasil.

Participation of the authors

Jefferson Westarb Mota conceived the article. Fernando Hellmann and Jucélia Maria Guedert helped design the study and write the article. Marta Verdi and Silvia Cardoso Bittencourt critically reviewed the text.

Received: 3.1.2021

Revised: 8.10.2022

Approved: 8.15.2022